Mirati's KRAS InhibitorKRAS Inhibitor Demonstrates Encouraging Clinical Profile in Latest Data Drop
06 Dec 2022
Clinical ResultPhase 3AcquisitionPhase 2Phase 1
Courtesy of Getty Images
Despite reporting positive data Monday from adagrasib for patients with first-line non-small cell lung cancer (NSCLC), shares of Mirati Therapeutics' dipped about 8% in after-hours trading Monday.
Adagrasib combined with Merck's Keytruda (pembrolizumab) showed positive preliminary data from the KRYSTAL-7 Phase II and KRYSTAL-1 Phase Ib cohort in first-line advanced/metastatic NSCLC patients with KRASG12C mutations.
"This data further underscores the potential of adagrasib as a well-tolerated treatment option for patients. Based on these data, we look forward to initiating a Phase III trial," Chuck Baum, president, founder and head of research and development for Mirati, said in a press statement.
Mirati will hold a conference call Wednesday.
"We believe the data continue to support the regimen's differentiated positioning relative to standard of care and are far more favorable than that of [Amgen's] Lumakras plus (immunotherapy)," JP Morgan analyst Eric Joseph wrote in a research note to investors.
Adagrasib is a highly selective and potent oral small molecule engineered to inhibit KRASG12C. Keytruda is Merck's anti-PD-L1 checkpoint inhibitorPD-L1 checkpoint inhibitor.
In various studies, adagrasib has shown a long half-life and extensive distribution throughout the body with a reasonable safety profile. It is being evaluated in several clinical studies in combination with other drugs in advanced solid tumors, with registration-enabling studies ongoing in NSCLC and colorectal cancer.
The latest data showed the drug combination helped approximately half of the previously untreated mNSCLC patients with manageable side effects. Mirati suggested the biggest advantage would be in patients with lower PDL1 levels and expects to initiate a Phase III trial in that patient population only, said company CEO David Meek.
BioSpace has reached out to Mirati for additional comment and details.
In the studies, 75 patients were enrolled and evaluable with a median follow-up of 3.5 months. Treatment-related adverse events (TRAEs) were primarily Grade 1, 2 and 3, with only 4% Grade 4 and none Grade 5. Only two patients discontinued both drugs due to TRAEs and two discontinued Keytruda. No patients discontinued adagrasib.
The two-drug combination demonstrated promising early clinical results across all PD-L1 subgroups in evaluable patients, showing an objective response rate of 49%. The ORR in a subset of response-evaluable patients enrolled at least six months before the data cutoff was 56%.
Of seven patients in the KRYSTAL-1 Phase Ib cohort, there was an ORR of 57% and a disease control rate (DCR) of 100%. The four patients who responded maintained that response for more than nine months, and two continued receiving treatment and maintained a response beyond 18 months.
"Initial results across all cohorts suggest the concurrent combination of adagrasib and pembrolizumab may provide a chemotherapy-free option for treatment-naïve NSCLC with a manageable safety pro encouraging clinical activity," said Pasi A. Janne, M.D., Ph.D., with the Dana Farber Cancer InstituteCancer Institute in a press release.
Late last week, Mirati announced plans to complete analysis of another program in NSCLC. The Phase III SAPPHIRE trial is evaluating sitravatinib in combination with Bristol Myers Squibb's checkpoint inhibitor Opdivo. The combination is being developed as a third- or fourth-line treatment for NSCLC patients. The company expects final data analysis by mid-2023.
Buyout Rumors Continue
Mirati has been a rumored acquisition target for some time. Last year, Merck was said to be considering buying the company. About two weeks ago, rumors swirled yet again that Mirati was a takeover target, although no specific buyers were mentioned, according to Bloomberg.
The company has a market cap of $5.1 billion and would be a target for companies interested in bolt-on deals to bolster their oncology pipelines. Its pipeline includes adagrasib, MRTX1133, sitravatinib and MRTX1719, a synthetic lethal PRMT5 inhibitorPRMT5 inhibitor.
Mirati also has discovery programs for mutant KRAS inhibitorsmutant KRAS inhibitors in solid tumors and programs for KRAS signal-modifying compounds that inhibit SOS1 in solid tumors.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.